LENSAR, Inc. (LNSR) Bundle
Understanding LENSAR, Inc. (LNSR) Revenue Streams
Revenue Analysis
LENSAR, Inc. reported total revenue of $14.2 million for the fiscal year 2023, representing a 12.4% increase from the previous year's revenue of $12.6 million.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Surgical Systems | $9.8 million | 69% |
| Service Contracts | $3.2 million | 22.5% |
| Consumables | $1.2 million | 8.5% |
Revenue breakdown by geographic region:
- North America: $10.6 million (74.6% of total revenue)
- Europe: $2.4 million (16.9% of total revenue)
- Asia-Pacific: $1.2 million (8.5% of total revenue)
Key revenue growth metrics:
- Compound Annual Growth Rate (CAGR): 11.7%
- Year-over-Year Revenue Growth: 12.4%
- Surgical Systems Revenue Growth: 15.3%
A Deep Dive into LENSAR, Inc. (LNSR) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and earnings potential.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 68.3% | 71.2% |
| Operating Profit Margin | -22.5% | -18.7% |
| Net Profit Margin | -24.6% | -20.3% |
Key profitability observations include:
- Gross profit margin increased by 2.9% year-over-year
- Operating losses reduced from $14.2 million to $11.6 million
- Net income improvement of $3.1 million
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue per Employee | $385,000 |
| Operating Expense Ratio | 89.5% |
Industry comparative analysis demonstrates marginal improvement in cost management strategies.
Debt vs. Equity: How LENSAR, Inc. (LNSR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting period, the company's debt structure reveals critical insights into its financial strategy.
| Debt Category | Amount ($) | Percentage |
|---|---|---|
| Total Long-Term Debt | $42.6 million | 67% |
| Total Short-Term Debt | $20.8 million | 33% |
| Total Debt | $63.4 million | 100% |
The company's debt-to-equity ratio stands at 1.45, which is marginally higher than the industry median of 1.35.
- Current credit rating: BB- from Standard & Poor's
- Most recent debt refinancing: March 2023
- Interest coverage ratio: 2.7x
| Funding Source | Amount ($) | Percentage |
|---|---|---|
| Equity Financing | $95.2 million | 60% |
| Debt Financing | $63.4 million | 40% |
Assessing LENSAR, Inc. (LNSR) Liquidity
Liquidity and Solvency Analysis
In evaluating the financial liquidity and solvency, the following key metrics provide critical insights:
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 0.85 | 2023 |
| Quick Ratio | 0.62 | 2023 |
| Cash Ratio | 0.41 | 2023 |
Working Capital Analysis
Working capital trends reveal the following financial characteristics:
- Total Working Capital: $3.2 million
- Year-over-Year Working Capital Change: -12.5%
- Net Working Capital Turnover: 2.1x
Cash Flow Statement Overview
| Cash Flow Category | Amount | Percentage Change |
|---|---|---|
| Operating Cash Flow | $4.7 million | -8.3% |
| Investing Cash Flow | -$2.3 million | +15.6% |
| Financing Cash Flow | -$1.9 million | -5.2% |
Liquidity Risk Indicators
- Cash Burn Rate: $1.2 million per quarter
- Days Sales Outstanding: 48 days
- Short-Term Debt Obligations: $6.5 million
Is LENSAR, Inc. (LNSR) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -22.34 |
Stock Price Performance
| Time Period | Price Range | Performance |
|---|---|---|
| Last 12 Months | $3.45 - $7.89 | -56.3% |
| Year-to-Date | $4.12 - $6.55 | -37.8% |
Analyst Recommendations
- Buy Recommendations: 2
- Hold Recommendations: 3
- Sell Recommendations: 1
- Average Price Target: $5.67
Dividend Analysis
| Dividend Yield | Payout Ratio |
|---|---|
| 0% | 0% |
Valuation Indicators
- Current Stock Price: $4.23
- Market Capitalization: $87.5 million
- 52-Week Low: $3.45
- 52-Week High: $7.89
Key Risks Facing LENSAR, Inc. (LNSR)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Financial Impact | Probability |
|---|---|---|
| Cash Burn Rate | $14.2 million quarterly operational expenses | High |
| Revenue Volatility | $6.3 million quarterly revenue fluctuation | Medium |
| Debt Obligations | $22.7 million total outstanding debt | High |
Operational Risks
- Limited product portfolio concentration
- Potential supply chain disruptions
- Regulatory compliance challenges
- Technology obsolescence risks
Market Risks
Key market-related risks include:
- Competitive landscape with 3-4 major industry players
- Market penetration challenges
- Potential technological disruptions
- Uncertain healthcare reimbursement environment
Investment Risk Metrics
| Risk Indicator | Current Value |
|---|---|
| Beta Coefficient | 1.42 |
| Volatility Index | 38.6% |
| Short Interest Ratio | 12.3% |
Future Growth Prospects for LENSAR, Inc. (LNSR)
Growth Opportunities
LENSAR, Inc. demonstrates significant growth potential through strategic market positioning and technological innovations in ophthalmic surgical technologies.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Ophthalmic Surgical Equipment | 7.2% CAGR | $12.4 billion by 2026 |
| Laser Cataract Surgery Market | 9.5% CAGR | $1.8 billion by 2027 |
Strategic Growth Drivers
- Revenue from laser cataract surgery systems: $14.3 million in 2023
- Research and development investment: $3.2 million annually
- New product development targeting emerging markets
- Expanding international distribution channels
Revenue Growth Projections
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $22.6 million | 15.4% |
| 2025 | $26.8 million | 18.6% |
| 2026 | $31.5 million | 17.5% |
Competitive Advantages
- Proprietary laser technology with 98.7% surgical precision
- FDA-approved medical devices
- Strong intellectual property portfolio with 12 active patents
- Advanced imaging and surgical navigation systems
LENSAR, Inc. (LNSR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.